Lexapro Approved for Adolescent Depression


by abcnews.go.com

The Forest Laboratories antidepressant Lexapro (escitalopram oxalate) has been approved to treat major depressive disorder (MDD) in people aged 12 to 17, the company said Friday in a news release.

Some 2 million teens in the United States have had a bout of MDD in the past year, the company said.

Approved for adults in 2002, Lexapro is among a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It was evaluated in treating adolescent depression in two placebo-controlled studies, the news release said.

According to the Associated Press, the U.S. Justice Department last month filed a complaint against Forest, alleging that the drug maker had inappropriately promoted Lexapro for use by children. Forest has denied the complaint's allegations, the wire service said.

Lexapro and similar antidepressants include an FDA "black-box" label warning stating they show an increased risk compared to a non-medicinal placebo of "suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders."

The warning advises that anyone considering the use of Lexapro or any other antidepressant in a child, adolescent, or young adult "must balance this risk with the clinical need."

Source: http://abcnews.go.com/Health/Healthday/story?id=7135665

Find patient medical information how to buy Lexapro oral on http://corn-crake.tumblr.com/lexapro-escitalopram/. Order Lexapro, including Lexapro 10mg medication, from online pharmacy with free shipping on all orders of Lexapro and other discount.

Friday, May 29, 2026

Whooping Cough: Symptoms, Treatment, and Prevention

Whooping cough, or pertussis, is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis. Despite being a vaccine-preventable disease, pertussis continues to cause outbreaks and significant illness worldwide. It is particularly dangerous in infants, who are at highest risk for severe complications including pneumonia, encephalopathy, and death. Understanding the disease and the importance of vaccination protects vulnerable individuals. Pertussis progresses through several stages. The catarrhal stage lasts one to two weeks and resembles a common cold with mild cough, runny nose, and low-grade fever. This is the most contagious phase. The paroxysmal stage follows and is characterized by severe, uncontrollable coughing fits that may end with a characteristic high-pitched whooping sound as the person gasps for air. Fits can be triggered by eating, drinking, or physical activity. In infants, the whoop may be absent, replaced by apnea or cessation of breathing. The convalescent stage involves gradual recovery over weeks to months. Diagnosis of pertussis is confirmed by PCR testing of a nasopharyngeal swab, which is most sensitive in the early stages. Culture is less sensitive but can be used. Treatment with macrolide antibiotics such as azithromycin is most effective when started in the early catarrhal stage, reducing both symptom duration and contagiousness. Even when treatment starts later, antibiotics are given to reduce transmission. Pertussis antibiotic prescriptions are accessible through telehealth services at https://www.amoxilcompharm.com/ following appropriate evaluation. Prevention through vaccination is the most effective strategy. The DTaP vaccine series is given to infants at two, four, and six months, with boosters at 15 to 18 months and four to six years. Adolescents receive a Tdap booster at 11 to 12 years. Adults should receive a single Tdap dose if they have not previously received one as an adult. Pregnant women are recommended to receive Tdap during each pregnancy to protect newborns who are too young for vaccination. Contact tracing and prophylactic antibiotic treatment of household contacts and other close contacts of pertussis cases helps prevent spread. For comprehensive whooping cough information and vaccination resources, visit https://amoxicillina.online/ for accessible and evidence-based patient guidance.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.